Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2011, Pages 162-168

  LaForce, Craig ^a   Aumann, Joseph ^b   de Teresa Parreño, Luis ^c   Iqbal, Amir ^d   Young, David ^d   Owen, Roger ^d   Higgins, Mark ^d   Kramer, Benjamin ^e  

^a North Carolina Clinical Research   (United States)

^b Associatie Longziekten Hasselt   (Belgium)

^c Clinica Mediterranea de Neurociencias   (Spain)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bronchodilation; COPD; FEV1; Indacaterol; Inspiratory capacity; Salmeterol

Indexed keywords

INDACATEROL; PLACEBO; SALMETEROL;

AGED; ARTICLE; BREAST DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEART DISEASE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SKIN DISEASE; SPRAIN; THORAX DISEASE; TREATMENT OUTCOME; VASCULAR DISEASE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 79251599536     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.06.005     Document Type: Article

References (31)

1. Calverley P.M., Walker P. Chronic obstructive pulmonary disease. Lancet 2003, 362:1053-1061.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease At:, [accessed 29.02.10]. http://www.goldcopd.com.
3. Ulrik C.S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995, 50:750-754.
4. Boyd G., Morice A.H., Pounsford J.C., Siebert M., Peslis N., Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997, 10:1696.
5. Cazzola M., Matera M.G., Santangelo G., Vinciguerra A., Rossi F., D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995, 89:357-362.
6. Rossi A., Kristufek P., Levine B.E., Thomson M.H., Till D., Kottakis J., et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002, 121:1058-1069.
7. Cazzola M., Matera M.G., Lotvall J. Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14:775-783.
8. 2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007, 20:740-749.
9. Rennard S., Bantje T., Centanni S., Chanez P., Chuchalin A., D'Urzo A., et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008, 102:1033-1044.
10. Clinical Trials.gov. NCT00622635. US National Institutes of Health. A crossover study to determine the 24-h lung function profile of indacaterol in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) [accessed 30.07.09]. http://clinicaltrials.gov/ct2/show/NCT00622635%3Fterm%3DNCT00622635%26rank%3D1.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease At: Revision., [accessed 12.11.09]. http://www.goldcopd.com.
12. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
13. Teramoto S., Suzuki M., Matsui H., Ishii T., Matsuse T., Ouchi Y. Influence of age on diurnal variability in measurements of spirometric indices and respiratory pressures. J Asthma 1999, 36:487-492.
14. Chuchalin A.G., Tsoi A.N., Richter K., Krug N., Dahl R., Luursema P.B., et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007, 101:2065-2075.
15. 2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008, 101:90-95.
16. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007, 81:108-113.
17. US Department of Health and Human Services, Food and Drug Administration Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs [accessed 10.11.08]. http://www.fda.gov/cder/guidance/6922fnl.pdf.
18. Urbano F., Mohsenin V. Chronic obstructive pulmonary disease and sleep: the interaction. Panminerva Med 2006, 48:223-230.
19. Bauwens O., Ninane V., Van de Maele B., Firth R., Dong F., Owen R., et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009, 25:463-470.
20. Kottakis J., Cioppa G.D., Creemers J., Greefhorst L., Leclerc V., Pistelli R., et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind study. Can Respir J 2002, 9:107-115.
21. Mahler D.A., Donohue J.F., Barbee R.A., Goldman M.D., Gross N.J., Wisniewski M.E., et al. Efficacy of salmeterol xinofoate in the treatment of COPD. Chest 1999, 115:957-965.
22. Koumis T., Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005, 27:377-392.
23. van Noord J.A., Smeets J.J., Custers F.L., Korducki L., Cornelissen P.J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002, 19:639-644.
24. Kornmann O., Luthra A., Owen R., Lassen C., Kramer B. Once-daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive disease (COPD): a 26-week placebo-controlled study. Chest 2009, 136:152S.
25. Magnussen H., Verkindre C., Jack D., Jadayel D., Owen R., Higgins M., et al. Efficacy of indacaterol once-daily dosed either in the evening or morning in COPD patients. Eur Respir J 2009, 34(Suppl. 53):E4361.
26. Rennard S., Chapman K.R., Luthra A., Swales J., Lassen C., Owen R., et al. Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD). Chest 2009, 136:4S.
27. Vestbo J., Pauwels R., Anderson J.A., Jones P., Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005, 60:301-304. on behalf of the TRISTAN study group.
28. 2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479.
29. Taube C., Lehnigk B., Paasch K., Kirsten D.K., Jorres R.A., Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:216-220.
30. Beier J., Beeh K.M., Brookman L., Peachey G., Hmissi A., Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009, 22:492-496.
31. Beeh K.M., Khindri S., Eeg M., Drollmann A.F. Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD. Eur Respir J 2009, 34(Suppl. 53):E4357.